Cellular penetration and antisense activity by a phenoxazine- substituted heptanucleotide

Nature Biotechnology

Volumn 17, Issue 1, 1999, Pages 48-52

  Flanagan, W Michael ^a   Wagner, Richard W ^b   Grant, Deborah ^a   Lin, Kuei Ying ^a   Matteucci, Mark D ^a  

^a GILEAD SCIENCES   (United States)

^b Phylos Inc   (United States)

Author keywords

Antisense oligonucleotides; Bioavailability; C 5 propyne; Cell permeation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHENOXAZINE DERIVATIVE;

ARTICLE; BIOAVAILABILITY; GENE TARGETING; GENE THERAPY; MICROINJECTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE; CELL MEMBRANE PERMEABILITY; HUMANS; IN SITU HYBRIDIZATION; KINETICS; MICE; MICROINJECTIONS; OLIGONUCLEOTIDES, ANTISENSE; OXAZINES; RATS; RIBONUCLEASE H, CALF THYMUS; RNA; SUBSTRATE SPECIFICITY;

EID: 0032902804     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/5220     Document Type: Article

References (45)

1. Wagner, R.W. 1995. The state of the art in antisense research. Nat. Med. 1:1116-1118.
2. Stein, C.A. 1997. Controversies in the cellular pharmacology of oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 7:207-209.
3. Stein, C.A. and Krieg, A.M. 1994. Problems in interpretation of data derived from in vitro and in vivo use of the antisense oligonucleotides. Antisense Res. and Dev. 4:67-69.
4. Nestle, F.O., Mitra, R.S., Bennett, C.F., Chan, H., and Nickoloff, B.J. 1994. Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J. Invest. Dermatol. 103:569-575.
5. Giachetti, C. and Chin, D.J. 1996. Increased oligonucleotide permeability in keratinocytes of artificial skin correlates with differentiation and altered membrane function. J. Invest. Dermatol. 107:256-262.
6. Wagner, R.W., Matteucci, M.D., Lewis, J.G., Gutierrez, A.J., Moulds, C., and Froehler, B.C. 1993. Antisense gene inhibition by oligonucleotide containing propyne pyrimidines. Science 260:1510-1513.
7. Bergan, R., Connell, Y., Fahmy, B., and Neckers, L. 1993. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 21:3567-3573.
8. Spiller, D.G. and Tidd, D.M. 1995. Nuclear delivery of oligodeoxynucleotide through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res. Dev. 5:13-21.
9. Partridge, M., Vincent, A., Matthews, P., Puma, J., Stein, D., and Summerton, J. 1996. A simple method for delivering morpholino antisense oligonucleotides into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev. 6:169-175.
10. Pichon, C., Freulon, I., Midoux, P., Mayer, R., Monsigny, M., and Roche, A.-C. 1997. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Dev. 7:335-343.
11. Lewis, J.G., Lin, K.Y., Kothavale, A., Flanagan, W.M., Matteucci, M.D., DePrince, R.B. et al. 1996. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA 93:3176-3181.
12. Zelphati, O. and Francis C. Szoka, J. 1996. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13:1367-1372.
13. Marcusson, E.G., Bhat, B., Manoharan, M., Bennett, C.F., and Dean, N.M. 1998. Phosphorothioate oligodeoxyribonucleotides disassociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:2016-2023.
14. Matteucci, M. 1997. Oligonucleotide analogues: an overview. Ciba Found. Symp. 209:5-14.
15. Krieg, A.M., Tonkinson, J., Matson, S., Zhao, Q., Saxon, M., Zhang, L.-M. et al. 1993. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. USA 90:1048-1052.
16. Lu, X.-M., Fischman, A.J., Jyawook, S.L., Hendricks, K., Tompkins, R.G., and Yarmush, M.L. 1994. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nucl. Med. 35:269-275.
17. 32P]-labeled phosphodoester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate. Drug Metab. Disp. 23:55-59.
18. Hughes, J.A., Bennett, C.F., Cook, P.D., Guinosso, C.J., Mirabelli, C.K., and Juliano, R.L. 1994. Lipid membrane permeability of 2′-modified derivatives of phosphorothioate oligonucleotides. J. Pharm. Sci. 83:597-600.
19. Wagner, R.W., Matteucci, M.D., Grant, D., Huang, T., and Froehler, B.C. 1996. Potent and selective inhibition of gene expression by an antisense neptanucleotide. Nat. Biotechnol. 14:840-844.
20. Wagner, R.W. and Flanagan, W.M. 1997. Antisense technology and prospects for therapy of infectious disease and cancer. Mol. Med. Today 3:31-38.
21. Loke, S.L., Stein, C.A., Zhang, X.H., Mori, K., Nakanishi, M., Subasinghe, C. et al. 1989. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86:3474-3478.
22. Miller, P.S., Yano, J., Yano, E., Carroll, C., Jayaraman, K., and Ts'o, P.O.P 1979. Synthesis and characterization of dideoxyribonucleoside methyl phosphonates. Biochemistry 18:5134-5143.
23. Jones, R.J., Lin, K.-Y., Milligan, J.F., Wadwani, S., and Matteucci, M.D. 1993. Synthesis and binding properties of pyrimidine oligodeoxynucleoside analogs containing neutral phosphodiester replacements: the formacetal and 3′-thioformacetal internucleoside linkages. J. Org. Chem. 58:2983-2991.
24. Vasseur, J.-J., Debart, F., Sanghvi, Y.S., and Cook, P.D. 1992. Oligonucleosides: Synthesis of a novel methylhydroxylamine-linked nucleoside dimer and its incorporation into antisense sequences. J. Am. Chem. Soc. 114:4006-4007.
25. Nielsen, P.E., Egholm, M., and Buchardt, O. 1994. A DNA mimic with a peptide backbone. Bioconjug. Chem. 5:3-7.
26. Lin, K.-Y., Jones, R.J., and Matteucci, M. 1995. Synthesis and incorporation into oligodeoxynucleotides which have enhanced binding to complementary RNA. J. Am. Chem. Soc. 117:3873-3874.
27. Lima, W.F. and Crooke, S.T. 1997. Binding affinity and specificity of Escherichia coli RNAse H1: Impact of the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36:390-398.
28. Moulds, C., Lewis, J.G., Froehler, B.C., Grant, D., Huang, T., Milligan, J.F. et al. 1995. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry 34:5044-5053.
29. Flores-Rozas, H. and Hurwitz, J. 1993. Characterization of a new RNA helicase from nuclear extracts of HeLa cells which translocates in the 5′ to 3′ direction. J. Biol. Chem. 268:21372-21383.
30. Monia, B.P., Johnston, J.F., Greiger, T., Muller, M., and Fabbro, D. 1996. Antitumor activity of a phosphorothioate antisense oligonucleotide targeted against c-raf kinase. Nat. Med. 2:668-675.
31. McKay, R. and Dean, M.N. 1994. Inhibition of protein kinase C-alpha expression in mice after systematic administration of phosphorothioate. Proc. Natl. Acad. Sci. USA 91:1762-1766.
32. Stepkowski, S.M., Tu, T., Condon, T.P., and Bennett, C.F. 1994. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 5336-5346.
33. Plenat, F. 1996. Animal models of antisense oligonucleotides: lessons for use in humans. Mol. Med. Today 2:250-257.
34. Flanagan, W.M. 1998. Antisense comes of age. Cancer and Metastasis Reviews 17:169-176.
35. Srinivasan, S.K. and Iversen, P. 1995. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9:129-137.
36. Bijsterbosch, M.K., Manoharan, M., Rump, E.T., Vrueh, R.L.A.D., Veghel, R.V., Tivel, K.L. et al. 1997. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. 25:3290-3296.
37. Agrawal, S., Temsamani, J., Galbraith, W., and Tang, J. 1995. Pharmacokinetics of antisense oligonucleotides. Drug Disp. 28:7-16.
38. Crooke, S.T., Graham, M.J., Zuckerman, J.E., Brooks, D., Conklin, B.S., Cummins, L.L. et al. 1996. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 923-937.
39. Geary, R.S., Leeds, J.M., Henry, S.P., Monteith, D.K., and Levin, A.A. 1997. Antisense oligonucleotide inhibitors for the treatment of cancer: pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-cancer Drug Des. 12:383-393.
40. Delong, R.K., Nolting, A., Fisher, M., Chen, Q., Wickstrom, E., Kligshteyn, M. et al. 1997. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice, Antisense Nucleic Acid Drug Dev. 7:71-77.
41. Fisher, T.L., Terhorst, T., Cao, X., and Wagner, R.W. 1993. Intracellular disposition and metabolism of fluorescently labeled unmodified and modified oligonucleotides microinjected into mammalian cells Nucleic Acids Res. 21:3857-3865.
42. Froehler, B.C., Wadwani, S., Terhorst, T.J., and Gerrard, S.R. 1992. Oligodeoxynucleotides containing C-5 propyne analogs of 2′-deoxyuridine and 2′-deoxycytidine. Tetrahedron Lett. 33:5307-5310.
43. Froehler, B.C., Jones, R.J., Cao, X., and Terhorst, T.J. 1993. Oligonucleotides derived from 5-(1-propynyl)-2′-O-allyl-uridine and 5-(1-propynyl)-2′-allyl-cytidine: Synthesis and RNA duplex formation. Tetrahedron Lett. 34:1003-1006.
44. Flanagan, W.M., Su, L.L., and Wagner, R.W. 1996. Elucidation of gene function using C-5 propyne antisense oligonucleotides. Nat. Biotechnol. 14:1139-1145.
45. Gutierrez, A.J., Matteucci, M.D., Grant, D., Matsumura, S., Wagner, R.W., and Froehler, B.C. 1997. Antisense gene inhibition by C-5-substituted deoxyuridine-containing oligodeoxynucleotides. Biochemistry 36:743-748.